Lv1
24 积分 2022-01-27 加入
Cell-surface targets for prostate cancer therapeutics
16天前
已完结
Systematic profiling of tumor-associated antigen expression for antibody-drug conjugate in prostate cancer
16天前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
29天前
已完结
Cancer burden and control in China: landscape, trends and challenges
1个月前
已完结
Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADO
1个月前
已完结
Revisiting the Role of Bevacizumab in the Treatment of Breast Cancer
1个月前
已完结
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
1个月前
已完结
Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer
1个月前
已完结
Meta-analyses on progression-free survival as a surrogate endpoint for overall survival in triple-negative breast cancer
3个月前
已完结
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial
4个月前
已完结
皖公网安备34019202002308
